| Document Date: 2015-03-16 01:05:14
Open Document File Size: 103,31 KBShare Result on Facebook
City Vienna / / Company AEs / The PBAC / Subgroup / NS Subgroup / GE / Pfizer Australia Pty Ltd / ITT / / Country Austria / Australia / / Currency USD / / Event Product Issues / FDA Phase / Product Recall / / Facility Consumer Comments facility / / Holiday Commonwealth Day / / IndustryTerm therapy for progressive disease / treatment of metastatic renal cell cancer / updated literature search / therapy for metastatic renal cell cancer / / MedicalCondition cancers / Cancer / disease / Administrative Advice Note Response Evaluation Criteria In Solid Tumours / metastatic renal cell carcinoma / progressive disease / clear cell renal cell carcinoma / metastatic carcinoma / renal carcinoma / sunitinib-refractory metastatic renal cell carcinoma / fatigue / metastatic renal-cell carcinoma / lymphopenia / Stable disease / White D. Noninfectious pneumonitis / renal cell carcinoma / advanced renal cell carcinoma / infections / pneumonitis / Response Evaluation Criteria In Solid Tumours / variant renal cell carcinoma / metastatic renal cell cancer / / Organization Congress / World Health Organization / STC MAIC / / Person Max Qty / / Position Dental Medical Practitioners Nurse / Minister / Program GENERAL / nurse / General / / Product severity necessitating permanent treatment / Manufacturer AXITINIB / AXITINIB tablets / RECORD-1 / data / A4061051 / axitinib / / PublishedMedium British Journal of Cancer / American Journal of Respiratory and Critical Care Medicine / Journal of Clinical Oncology / /
SocialTag |
7.2 AXITINIB tablets, 1 mg & 5 mg; Inlyta®; Pfizer Australia Pty Ltd. Provisionally redacted Public Summary Document: Some of the content redacted from this PSD is still the subject of discussion between the Department